| |
Download our guide to learn how to navigate the complex European landscape and gain insights on how late-stage customization could make your European distribution simpler and more efficient. Download now.
|
|
Today’s Big NewsOct 17, 2023 |
| By Annalee Armstrong Biopharmas love to break the news of an M&A deal with a splashy number. Commercial milestones can represent as much as 40% of the so-called earnout potential for a deal—adding up to about $25 billion in potential. But how much of that is actually paid out in the end? |
|
|
|
By Nick Paul Taylor Evelo Biosciences’ last roll of the dice has come up snake eyes. After seeing its lead candidate flounder in the clinic, the biotech has revealed its next-generation asset performed worse than placebo in a phase 2 psoriasis trial, prompting it to start searching for strategic alternatives. |
By James Waldron Roche has signed its second molecular glue deal in a month, this time paying $50 million upfront to Monte Rosa Therapeutics for the use of its QuEEN platform to target cancer and neurological diseases previously considered out of reach. |
Sponsored by Tanvex CDMO Reacting to the growth of biotherapeutics, Tanvex BioPharma USA, Inc., is set to launch Tanvex CDMO, a full-service CDMO specializing in mammalian- and microbial-derived biologics and biosimilars. |
|
Best-in-class thermostability and excellent inhibitor tolerance deliver compatibility across a range of clinically relevant samples and superior results in pathogen detection assays. Lyophilization-friendly formats available. Learn more.
|
|
By Nick Paul Taylor Gilead wants first dibs on all Assembly Biosciences’ programs. Rather than buy the viral disease biotech, Gilead is paying $100 million upfront for opt-in rights on all Assembly’s current and future programs. |
By Annalee Armstrong SpliceBio is sparking up a new $216 million alliance with Roche’s gene therapy unit to develop a new treatment for an inherited retinal disease. |
By Max Bayer Ultragenyx and Mereo BioPharma are out with a new slice of data from a phase 2/3 trial of its brittle bone disease treatment, showing it significantly reduced the rate of fractures. The data continue to add momentum to setrusumab as phase 3 recruitment continues. |
By Max Bayer Aldyera came clean about the prospects of its dry eye disease med, revealing that the FDA could soon reject it due to review issues. The FDA had suggested the company run an additional clinical trial to confirm efficacy. |
By Helen Floersh NIH researchers have shown that replacing pre-treatment chemo with an antibody-drug conjugate can eliminate the risk of infertility among primates who receive a sickle cell gene therapy. |
By Angus Liu Thanks to a new FDA approval for Merck's Keytruda, a continuous immunotherapy regimen around surgery is now available for patients with early-stage non-small cell lung cancer. The drug's label already includes an overall survival win from a key trial. |
By Paige Minemyer The National Community Pharmacists Association has launched the latest salvo in its battle with pharmacy benefit managers over controversial fees. |
By Eric Sagonowsky Even after touting revenue and profit growth in the third quarter, Johnson & Johnson is busy getting ready for the looming loss of Stelara's exclusivity. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation. They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease. |
|
|---|
|
|
|
Learn how to improve yield and reproducibility with advanced sample prep for a variety of multiomics use cases, especially for suboptimal biospecimens. See how to get quality results from complex samples thanks to key innovations in ultrasonication. Learn more.
|
|
| Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| WhitepaperCell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
| WhitepaperUncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
| Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
| WhitepaperEconomic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
| WhitepaperFrom Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| |
|
